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Abstract 
Rationale: Cough is the most frequent reason for consultation with a family doctor, or with a general 
or respiratory physician. Treatment options are limited and one meta-analysis concluded that over-
the-counter remedies are ineffective. There is also increasing concern about their use in children. 
Environmental irritants such as air pollution and cigarette smoke are thought to evoke cough by 
stimulating airway sensory nerves; however, how this occurs is not fully understood. 
Objectives: We hypothesized that the TRPA1 (transient receptor potential cation channel, subfamily 
A, member 1) receptor may have a role as a novel target for tussive agents given that many potential 
irritants have been shown to activate this channel. 
Methods: We investigated the effect of TRPA1 ligands on vagal sensory nerve activity in vitro and in 
guinea pig and human tussive challenge models. 
Measurements and Main Results: We demonstrated that TRPA1 agonists such as acrolein activate 
cloned human TRPA1 channels in HEK293 cells and also vagal sensory nerves in murine, guinea pig, 
and human tissues. A role for TRPA1 was confirmed, using specific inhibitors and tissue from 
Trpa1−/− gene–deleted animals. Finally, TRPA1 ligands evoked reproducible tussive responses in 
both a guinea pig model and normal volunteers. 
Conclusions: This study identifies the TRPA1 receptor as a promiscuous receptor, activated by a wide 
range of stimuli, making it a perfect target for triggering cough and as such one of the most 
promising targets currently identified for the development of antitussive drugs. 
 
Cough is the most frequent reason for consultation with a family doctor (1), or with a general or 
respiratory physician. Patients with chronic cough probably account for 10–38% of respiratory 
outpatient practice in the United States (2). Chronic cough, of various etiologies, is a common 
presentation to specialist respiratory clinics and is reported as a troublesome symptom by 7% of the 
population (3). Treatment options are limited. A meta-analysis concluded that over-the-counter 
cough remedies are ineffective (4), and there is increasing concern about the use of over-the-
counter therapies in children. Despite its importance our understanding of the mechanisms that 
provoke cough is poor. 
Ion channels of the transient receptor potential (TRP) class have been implicated in the afferent 
sensory loop of the cough reflex (5–7) and in the heightened cough sensitivity seen in disease (8). 
Agonists of the TRPV1 (transient receptor potential cation channel, subfamily V, member 1) 
capsaicin receptor, such as vanilloids and protons, are among the most potent chemical stimuli that 
cause cough (5–7). Another TRP receptor, TRPA1 (transient receptor potential cation channel, 
subfamily A, member 1), which is not activated by capsaicin, has been shown to bind ligands such as 
acrolein, which is present in air pollution and the acrid smoke from organic material (9). We 
hypothesized that TRPA1 may have a role as a novel target for tussive agents. 
TRPA1 is a Ca2+-permeant nonselective channel with 14 ankyrin repeats in its amino terminus, 
which belongs to the larger TRP family (10). TRPA1 has been characterized as a thermoreceptor that 
is activated by cold temperature (11). In addition, TRPA1 channels are activated by a range of natural 
products such as allyl isothiocyanate, allicin, and cannabinol, found in mustard oil, garlic, and 
cannabis, respectively (12–14). The channel is also activated by a multitude of environmental 
irritants such as isothiocyanate, cinnamaldehyde, and acrolein. The latter is present in air pollution, 
vehicle exhaust, and cigarette smoke (9, 15–20). TRPA1 is expressed primarily in small-diameter, 
nociceptive neurons where its activation probably contributes to the perception of noxious stimuli 
and the phenomena known as inflammatory hyperalgesia and neurogenic inflammation (9, 17, 19). 
The respiratory tract is innervated by sensory afferent nerves including the myelinated, rapidly 
adapting receptors and the nonmyelinated, chemosensitive C-fibers, which are activated by 
mechanical and chemical stimuli (21, 22). Activation of these vagal sensory afferents leads to central 
reflexes including cough. It has been demonstrated that stimulating TRPA1 channels activates vagal 
bronchopulmonary C-fibers in the guinea pig and rodent lung (23–25). 
The aim of these experiments was to employ a series of preclinical and clinical studies to determine, 
for the first time, whether activation of the TRPA1 channel can evoke a tussive response. Evidence to 
this effect could result in a deeper understanding of the pathogenesis of cough and lead to the 
development of novel treatment modalities. 
METHODS 
Functional Characterization of Cloned TRPA1 Expressed in HEK293 Cells 
TRPA1-expressing HEK293 cells and the method used to measure increases in intracellular calcium 
levels in this study have been described previously (26; and see the online supplement). 
Animals 
Male Dunkin-Hartley guinea pigs (300–500 g) were housed in a temperature-controlled (21°C) room 
with food and water freely available for at least 1 week before commencing the experiment. The 
experiments were performed in accordance with the U.K. Home Office guidelines for animal welfare 
based on the Animals (Scientific Procedures) Act of 1986. 
Effect of TRPA1 Ligands on Isolated Vagal Nerve Preparation 
To demonstrate a functional response of TRPA1 channel activation in native tissue we used our fully 
characterized isolated vagal nerve preparation as described in previous publications (27, 28). 
Sensory nerve responses to the two TRPA1 agonists, acrolein and cinnamaldehyde, were 
determined. For these experiments only one response to one agonist was obtained in each segment 
of vagus. We also performed experiments with the selective TRPA1 inhibitor, HC-030031, or vehicle 
(dimethyl sulfoxide, 0.1% [vol/vol]) (17). To demonstrate antagonist selectivity HC-030031 was also 
tested against the TRPV1 agonist capsaicin, using a parallel protocol. To provide additional proof-of-
concept data an alternative antagonist was also used, AP-18 (29). 
To further confirm that the response observed was via activation of the TRPA1 channel we 
performed parallel agonist (acrolein) experiments using vagal tissue from wild-type and Trpa1−/− 
gene-deleted mice (Jackson Laboratory, Bar Harbor, ME). We confirmed the deletion of the Trpa1−/− 
gene in the knockout mice, and not the wild type, using standard genotyping techniques. 
Effect of TRPA1 Ligand Acrolein in Guinea Pig Conscious Cough Model 
Cough was detected both by pressure change and by sound and recorded with a Buxco cough 
analyzer (Buxco, Wilmington, NC) as previously described (28). Guinea pigs received an aerosol of 
vehicle (0.9% sterile saline, n = 12) or acrolein (10, 30, 100, or 300 mM, n = 12, concentration derived 
from a preliminary study) for 5 minutes and coughs were counted during this period and for a 
further 5 minutes with the Buxco cough analyzer. 
Having established a submaximal dose of acrolein, we confirmed the role of TRPA1 using the 
selective inhibitor HC-030031. Guinea pigs were dosed with vehicle (0.5% methyl cellulose in sterile 
saline at 1 ml/kg, administered intraperitoneally, n = 12) or HC-030031 (300 mg/kg, dose selected 
from data published by McNamara and colleagues [17]). One hour later the guinea pigs were 
exposed to a submaximal dose of TRPA1 agonist and cough was monitored as outlined previously. 
In Vitro Functional Characterization of TRPA1 in Isolated Human Vagal Tissue 
Briefly, human trachea, with branches of the cervical vagus still attached, was obtained from three 
unused donor tissue samples surplus to clinical requirement (two males, 32–55 yr of age) collected 
for heart–lung transplantation. Relevant approvals were obtained from the next of kin and the Royal 
Brompton and Harefield Trust Ethics Committee. The isolated human vagus was exposed to a TRPA1 
agonist and antagonist as described previously for the guinea pig experiments. 
Characterization of Tussive Response to Inhalation of TRPA1 Agonist in Human Volunteers 
Healthy male and female, nonsmoking volunteers with normal lung function were entered into a 
randomized, crossover study of inhalational cough challenge of three tussive agents. Informed 
written consent was obtained from all the volunteers and the study was approved by the Hull and 
East Yorkshire Ethics Committee. Volunteers were randomized to inhalational cough challenge with 
the TRPA1 agonist diluent or cinnamaldehyde or capsaicin or citric acid. At Visit 1 a baseline cough 
challenge was performed and repeated 1 hour later with the same agent. The subjects were asked to 
return on two occasions 2–3 days apart when the protocol was repeated with an alternative cough 
stimulus. Each subject was recalled 2–3 days later for Visit 4 when a subthreshold dose (i.e., the dose 
below that evoking cough) of cinnamaldehyde or diluent was administered followed by a repeat 
cough challenge to capsaicin and citric acid, which was performed 1 hour later. This was repeated 2–
3 days later at Visit 5 with the alternative subthreshold inhalation. Safety assessments were 
performed at all these visits. 
Nebulizations were performed with a MEFAR MB3 dosimeter (Mefar Elletromedicale, Bovezzo, Italy) 
with a Respironics nebulizer chamber and mouthpiece according to our previously described 
methodology (30). The dosimeter was set to nebulize for 1 second and 2 ml of the agent was 
instilled into the nebulizer chamber. Coughs induced were assessed during the subsequent 15 
seconds after the nebulization. Serial dilutions from stock (1 M citric acid, 1 mM capsaicin) were 
made with 0.9% saline whereas 50% ethanol was used as the diluent for cinnamaldehyde (800 mM). 
Compounds and Materials 
Fluo-3 acetoxymethyl ester and LipofectAMINE 2000 were purchased from Invitrogen (Paisley, UK). 
Penicillin–streptomycin, fetal calf serum, Dulbecco's modified Eagle's medium, sodium pyruvate, and 
geneticin (G418) were all bought from GIBCO (Paisley, UK). The TRPA1 inhibitor HC-030031 was 
purchased from ChemBridge (San Diego, CA). All other agents were purchased from Sigma-Aldrich 
(Poole, Dorset, UK). All other details are in the online supplement. 
Data Analysis and Statistics 
Antagonism of TRPA1 agonists was analyzed by two-tailed paired t test, comparing responses to 
agonist (in the same piece of vagus nerve) in the absence and presence of antagonist. Responses to 
TRPA1 ligands in gene-deleted mice were analyzed by Kruskal-Wallis test for multiple comparisons 
with Dunn's post-hoc test, comparing the responses in each TRPA1 receptor knockout with those of 
the wild-type control. Inhibition of acrolein-induced cough was analyzed by Mann-Whitney U test for 
nonparametric data. Data are presented as means ± SEM and statistical significance is denoted as *P 
< 0.05. 
In the clinical study end points were taken as the concentration at which two or more coughs were 
induced (C2) and at which five or more coughs were induced (C5). For the purposes of statistical 
analysis the data were log transformed. SPSS version 13.0 was used for statistical analysis. Paired t 
tests or Wilcoxon analysis was performed when applicable. A P value of 0.05 or less was considered 
statistically significant. 
RESULTS 
In Vitro Functional Characterization of TRPA1 Ligands on Cloned Human TRPA1 Channels in 
HEK293 Cells 
The TRPA1 receptor was successfully cloned from primary human fibroblasts and permanently 
expressed in HEK293 cells. Reverse transcription-polymerase chain reaction showed that HEK293 
cells do not endogenously express TRPA1 mRNA (see Figure E1 in the online supplement). 
Calcium signaling was used to assess agonist-induced activation of TRPA1-HEK cells (Figure 1). 
hTRPA1-HEK cells responded to both cinnamaldehyde and acrolein in a concentration-dependent 
manner (Figure 1). None of the agonists tested stimulated an observable increase in calcium in 
nontransfected or mock-transfected HEK cells or in hTRPV1-HEK cells (Figure 1). These results also 
demonstrated that HC-030031 caused inhibition of both cinnamaldehyde- and acrolein-evoked 
responses in a concentration-dependent manner. 
Figure 1. 
 
Calcium signaling was used to assess agonist induced activation of TRPA1-HEK cells and agonist-
induced activation of TRPA1-HEK cells after preincubation with the antagonist HC-030031. (A) 
Cinnamaldehyde concentration–response curve (squares) in hTRPA1-HEK cells. hTRPV1-HEK cells 
failed to respond to 100 μM cinnamaldehyde (triangle). (B) Acrolein concentration–response 
curve (squares) in hTRPA1-HEK cells. hTRPV1-HEK cells failed to respond to 300 μM acrolein 
(triangle). (C) Effect of increasing HC-030031 concentrations on cinnamaldehyde (30 μM)-evoked 
calcium responses. (D) Effect of increasing HC-030031 concentrations on acrolein (3 μM)-evoked 
calcium responses. Results are expressed as means ± SEM of up to seven experiments, each 
performed in duplicate. *Statistical significance (P < 0.05) from vehicle-treated group. 
Effect of TRPA1 Ligands on Isolated Guinea Pig Vagal Nerve Preparation 
Tussive agents such as capsaicin, low-pH solutions, and prostaglandin E2 (PGE2) are known vagal 
sensory nerve stimulants and as such isolated guinea pig, murine, and human vagus nerve 
preparations have been shown to elicit nerve depolarization responses to these stimulants (27, 28, 
31). Furthermore, these agents are also known tussigenic agents in human and animal studies (5, 6, 
32). These data suggest that the isolated vagus nerve is a useful and predictive preparation for 
conducting comprehensive pharmacological assessments of agents that may activate or inhibit 
sensory nerve function and thus the cough reflex. Previous data also suggest that the information 
generated is broadly predictive of data generated in single afferent nerve fiber recording studies, 
further validating the use of the isolated vagus preparation. 
Therefore, to demonstrate a functional role for the TRPA1 channel in a native tissue, we 
demonstrated a concentration-related increase in the depolarization of the guinea pig isolated vagus 
(indicative of sensory nerve activation) with acrolein (Figure 2A). Furthermore, data obtained with 
cinnamaldehyde produced a similar pattern (see Figure E2 in the online supplement). To further 
confirm a role for TRPA1, we demonstrated that the selective TRPA1 inhibitors AP-18 and HC-030031 
blocked depolarization in response to acrolein (Figures 2B and 2C). However, HC-030031 did not 
affect responses evoked by capsaicin (Figure 2C). In addition, we have shown that the vagus from 
Trpa1−/− mice failed to respond to the TRPA1 agonist acrolein, but depolarized in response to a 





(A) Characterization of the depolarization (mV) responses elicited by isolated guinea pig vagus 
nerve preparations in response to the TRPA1 agonist acrolein. (B and C) Effect of TRPA1 channel 
blockers (AP-18, 1–10 μM; and HC-030031, 0.3–30 μM) on acrolein (300 μM)- or capsaicin (1 
μM)-induced depolarization of isolated guinea pig vagus nerve preparations. Values are 
presented as means ± SEM of the percentage inhibition of depolarization before and after drug 
superfusion (n = 4). (D) Depolarization (mV) in response to TRPA1 (acrolein, 1 mM)/TRPV1 
(capsaicin, 1 μM) agonists in vagal nerve tissue from wild-type and Trpa1−/− gene-deleted mice. 
Results are expressed as the mean ± SEM of four to six experiments. KO, knockout. 
Effect of TRPA1 Ligand Acrolein in a Conscious Guinea Pig Cough Model 
To demonstrate that the observations in the isolated tissue translate in vivo we exposed guinea pigs 
to aerosolized acrolein. As can be seen in Figure 3, the TRPA1 agonist caused a dose-related increase 
in coughs. To confirm that the response was through the TRPA1 channel we performed experiments 
in which the guinea pigs were pretreated with the TRPA1 inhibitor before exposure to acrolein. In 
these experiments HC-030031 significantly inhibited the tussive response to acrolein (Figure 3). 
Figure 3. 
  
(A) Dose response to inhaled acrolein in conscious male guinea pigs (n = 12). (B) Blockade of the 
tussive response to acrolein with the TRPA1 ion channel blocker HC-030031 (300 mg/kg). Guinea 
pigs were dosed with vehicle or HC-030031 one hour before the tussive challenge (n = 12). 
Statistical significance was determined by Mann-Whitney U test for nonparametric data. Data are 
presented as means ± SEM and statistical significance is denoted as *P < 0.05. 
In Vitro Functional Characterization of Response to TRPA1 in Isolated Human Vagal Tissue 
To demonstrate that the observations in guinea pigs and mice translated to humans we paralleled 
the key vagal experiments with tissue collected from donor lung samples. Figure 4 shows that the 
human vagus is activated by acrolein (Figure 4A) and that this response is inhibited by a TRPA1 
antagonist (Figure 4B). 
Figure 4. 
  
(A) Characterization of depolarization (mV) responses elicited by isolated human vagus nerve 
preparations in response to the TRPA1 agonist acrolein. Results are expressed as means ± SEM of 
three experiments. (B) A representative trace describing depolarization of isolated human vagus 
evoked by acrolein (1 mM) and inhibition in the presence of the TRPA1 antagonist AP-18 (10 μM). 
The response to acrolein is recovered after washout. (C) Concentration–response curve of 
cinnamaldehyde inhaled at baseline and repeated 1 hour later in human volunteers. 
Nebulizations were performed with the MEFAR MB3 dosimeter with a Respironics nebulizer 
chamber and mouthpiece. The dosimeter was set to nebulize for 1 second and 2 ml of the agent 
was instilled into the nebulizer chamber. Coughs induced were assessed during the subsequent 
15 seconds after the nebulization. 
Demonstration of Tussive Response to TRPA1 Agonist in Human Volunteers 
Ten subjects (6 males; mean age, 33.5 yr) were studied. Inhalation of nebulized cinnamaldehyde (but 
not diluent) induced cough in all subjects. One subject did not achieve C5 (the concentration 
inducing five or more coughs) at the highest concentration. One subject became nauseous at C2 (the 
concentration causing two or more coughs) and was withdrawn from further study. There was a 
distinct concentration–response relationship to inhaled cinnamaldehyde (Figure 4C). The median C2 
for the baseline cinnamaldehyde challenge was 200 mM (range, 125–not achieved) with no 
significant tachyphylaxis seen with the second challenge (median C2, 275 mM [range 125–800]). The 
median C5 was 312.5 mM (range, 125–not achieved) compared with 387.5 mM (range, 125–not 
achieved) at 1 hour from baseline. These values are compared with citric acid and capsaicin 
challenge in the same subject in Table 1. Citric acid was the only agent that showed significant 
tachyphylaxis (P = 0.02) for C5. The prior inhalation of a subthreshold dose of cinnamaldehyde or of 
the diluent did not have any effect on subsequent cough challenge. Inhalation of cinnamaldehyde 
was well tolerated with no adverse effects other than mild nausea in one person. 
TABLE 1. 
RESPONSE THRESHOLD FOR THE VARIOUS TUSSIVE CHALLENGES IN 10 
NORMAL SUBJECTS 








C2 200 275 n/a n/a
C5 313 388 n/a n/a
Citric acid (mM) C2 125 125 125 94
C5 200 250 250 250
Capsaicin (μM) C2 4 4 8 4
C5 
 
12 16 16 
 
16 
Shown are median C2 and C5 values at baseline and 1 hour after baseline for cinnamaldehyde, 
citric acid, and capsaicin as well as median C2 and C5 values after inhalation of subthreshold 
TRPA1 agonist and diluent. C2 is the concentration inhaled at which two or more coughs were 
recorded and C5 is the concentration at which five or more coughs were recorded. In the citric 




Inhalational exposure to numerous irritating gases, fumes, dusts, vapors, chemicals, and endogenous 
mediators can lead to the development of cough. It has long been established that TRPV1 receptor 
activation can elicit a cough response in both animal models and in humans (5–7). This receptor is 
polyvalent, and is activated by vanilloids (e.g., capsaicin), noxious heat (≥42°C), extracellular protons 
(pH ≤ 5.9), and endogenous lipids (e.g., anandamide) and eicosanoids [e.g., leukotriene B4, 12-(S)-
hydroperoxyeicosatetraenoic acid, and 15-(S)-hydroperoxyeicosatetraenoic acid]. However, it does 
not respond to many irritants known to initiate cough. The mechanism whereby a range of 
seemingly diverse irritants initiate acute and chronic cough has remained a mystery. These data have 
identified, for the first time, an alternative target for antitussive therapies that responds to known 
environmental irritants. 
We began by cloning human TRPA1 and permanently expressing it in HEK293 cells and 
demonstrated that the reported TRPA1 agonists activated this channel, confirming previous data 
(19, 24). In house we have extensively characterized robust and clinically relevant preclinical systems 
in which to test potential sensory nerve modulators (27, 28). As the guinea pig is the only small 
animal that possesses a cough reflex that resembles the human response we used the isolated 
guinea pig vagus in conjunction with an in vivo conscious guinea pig cough model (28). Using the 
isolated guinea pig vagus preparation we demonstrated that two different TRPA1 agonists were able 
to activate sensory nerves and that this response could be attenuated with selective TRPA1 
inhibitors. Similar data demonstrating inhibition of the TRPA1 channel with these inhibitors have 
been generated by other investigators (17–19, 29). To strengthen this pharmacological proof of 
concept we performed experiments with knockout mice. We demonstrated that TRPA1 and TRPV1 
agonists both activate vagal sensory nerves in the wild-type mice; but that depolarization was 
achieved only by the TRPV1 agonist capsaicin, on the isolated vagal preparations from mice from 
which the Trpa1 gene was deleted. Although the vagus is a useful and predictive preparation to use 
for a comprehensive pharmacological assessment of the activity of TRPA1 ligands on vagal sensory 
nerve activation the data should be viewed with some caution because pharmacological agents are 
applied to the axon of the isolated vagus nerve in vitro and not the nerve ending. The advantages 
and limitations of this preparation have been discussed at length in our previous publications (27, 
28) however, evidence to date suggests that the isolated vagus preparation is predictive of data 
generated with single-fiber electrophysiological preparations and data generated in the conscious 
guinea pig cough mode (33). Furthermore, it is consistent with electrophysiological evidence 
suggesting that functional TRPA1 channels exist in respiratory nociceptive sensory neurons and their 
terminals (24). Next, we were able to show a dose–response relationship between increasing 
challenges with a TRPA1 agonist and the number of coughs in a guinea pig model. What is more, we 
were able to attenuate this tussive response with a selective TRPA1 inhibitor. To demonstrate that 
the preclinical data generated in animal in vitro and in vivo models actually translated to humans, 
we paralleled the previous experiments, using human vagal tissue. 
With proof-of-concept data in an animal in vivo model and in human tissue in vitro we were able to 
move on with confidence to study normal human volunteers. The data from this study clearly show 
that a TRPA1 agonist causes a concentration-dependent cough in humans. The human cough 
response appears to be reproducible and without significant tachyphylaxis in this small data set. 
Agonizing TRPA1, using this protocol, does not appear to impact on cough responses to other tussive 
agents, suggesting a direct and specific response. 
The TRPA1 receptor is activated by a number of irritant chemicals including mustard oil (i.e., 
isothiocyanate), acrolein, garlic, formalin, allicin, wasabi, cinnamon oil, diallyl disulfide, allyl 
isothiocyanate, 4-hydroxynonenal, and 4-oxononenal (12–14, 16–18, 20, 23, 25). The mechanism of 
action would appear to be through covalent modification of cysteine residues within the cytosolic N 
terminus of TRPA1 by reactive electrophilic molecules (16). This mode of action could be significant 
in pathological situations given that oxidant stress induced by either an inflammatory response or by 
exogenous irritants, such as cigarette smoke, can generate reactive electrophilic molecules including 
acrolein and 4-hydroxynonenal. This also suggests that the TRPA1 receptor is a promiscuous 
receptor that can be activated by a wide range of stimuli, thus making it a perfect target for 
triggering protective cough reflexes. However, more work will be required to determine which of 
these putative agonists are sufficiently potent to stimulate cough in vivo. 
Interestingly, inflammation can lead to the formation of endogenous electrophilic compounds in vivo 
(34). Examples of such compounds are the cyclopentenone ring-containing A and J series 
prostaglandins, which are formed as nonenzymatic dehydration products of PGE2 and PGD2, 
respectively. Prostanoids that contain one or two electrophilic carbons such as 15PGJ2, Δ12-PGJ2, 8-
iso-PGA2, and PGA2 are therefore able to activate nociceptive neurons via direct interaction with 
TRPA1 (25). Furthermore, prostaglandins such as PGE2 and the inducible form of cyclooxygenase-2 
are elevated in respiratory disease states at the site of inflammation (35–37). Taken together, this 
information would suggest that reactive prostanoids and other endogenous TRPA1 ligands, which 
are produced in greater amounts during inflammation or oxidant stress, could evoke the cough seen 
in conditions such as asthma and chronic obstructive pulmonary disease. 
It is still unclear whether there is cooperation between TRPV1 and TRPA1 channels. Both are 
activated by tussive agents and so it could be possible that these TRP channels act in concert to elicit 
functional responses. The dependence of TRPA1 on Ca2+ may result in the activation of TRPA1 
channels by an overflow of Ca2+ in the locale of other activated channels without ever being 
modified by a reactive ligand. Furthermore, TRPA1 channels may also act as an amplifier of other 
Ca2+-mobilizing pathways, including activation of TRPV1 (38). However, whether this sort of 
cooperation exists in generating a cough reflex has yet to be determined. 
In conclusion, we have shown for the first time that activation of the TRPA1 channel can evoke a 
tussive response in humans. This novel and exciting finding could have major implications for 
understanding the pathogenesis of respiratory diseases and for the treatment of cough, which 
presents as a significant unmet medical need. Because of their central role and activation by a wide 
range of irritant and chemical substances, either by exogenous agents, endogenously produced 
mediators during inflammation, or by oxidant stress, we suggest TRPA1 channels should be 
considered as one of the most promising targets currently identified for the development of novel 
antitussive drugs. 
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